| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 20.16M | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | 0 |
| Revenue Growth % | - | - | 1.48% | -0.14% | -0.32% | 0.2% | -0.67% | -1% |
| Cost of Goods Sold | 26.59M | 51.08M | 91.75M | 132.25M | 186.95M | 253.07M | 411.24M | 592.23M |
| COGS % of Revenue | - | 2.53% | 1.83% | 3.08% | 6.36% | 7.15% | 35.51% | - |
| Gross Profit | -26.59M | -30.92M | -41.71M | -89.27M | -157.56M | -217.69M | -399.66M | -592.23M |
| Gross Margin % | - | -1.53% | -0.83% | -2.08% | -5.36% | -6.15% | -34.51% | - |
| Gross Profit Growth % | - | -0.16% | -0.35% | -1.14% | -0.76% | -0.38% | -0.84% | -0.48% |
| Operating Expenses | 4.54M | 9.41M | 12.41M | 21.43M | 30.45M | 40.59M | 87.52M | 97.3M |
| OpEx % of Revenue | - | 0.47% | 0.25% | 0.5% | 1.04% | 1.15% | 7.56% | - |
| Selling, General & Admin | 4.54M | 9.01M | 12.41M | 21.43M | 30.45M | 40.59M | 62.02M | 97.3M |
| SG&A % of Revenue | - | 0.45% | 0.25% | 0.5% | 1.04% | 1.15% | 5.36% | - |
| Research & Development | 26.59M | 51.08M | 91.75M | 132.25M | 186.95M | 253.07M | 423.14M | 592.23M |
| R&D % of Revenue | - | 2.53% | 1.83% | 3.08% | 6.36% | 7.15% | 36.54% | - |
| Other Operating Expenses | -26.59M | -50.68M | -91.75M | -132.25M | -186.95M | -253.07M | -397.64M | -592.23M |
| Operating Income | -31.13M | -40.33M | -54.12M | -110.7M | -188.01M | -258.28M | -487.19M | -689.52M |
| Operating Margin % | - | -2% | -1.08% | -2.58% | -6.4% | -7.3% | -42.07% | - |
| Operating Income Growth % | - | -0.3% | -0.34% | -1.05% | -0.7% | -0.37% | -0.89% | -0.42% |
| EBITDA | -29.94M | -38.56M | -50.78M | -104.15M | -180.68M | -248.62M | -482.18M | -677.7M |
| EBITDA Margin % | - | -1.91% | -1.01% | -2.42% | -6.15% | -7.03% | -41.64% | - |
| EBITDA Growth % | - | -0.29% | -0.32% | -1.05% | -0.73% | -0.38% | -0.94% | -0.41% |
| D&A (Non-Cash Add-back) | 1.19M | 1.76M | 3.34M | 6.54M | 7.33M | 9.66M | 5.01M | 11.82M |
| EBIT | -31.02M | -41.67M | -51.93M | -108.46M | -187.08M | -258.28M | -461.69M | -600.85M |
| Net Interest Income | 2K | 661K | 2.08M | 2.17M | 917K | 9.15M | 47.48M | 86.88M |
| Interest Income | 105K | 777K | 2.19M | 2.24M | 929K | 9.15M | 47.48M | 86.88M |
| Interest Expense | 103K | 116K | 106K | 71K | 12K | 0 | 0 | 0 |
| Other Income/Expense | 2K | -1.46M | 2.08M | 2.17M | 917K | 9.15M | 47.29M | 88.68M |
| Pretax Income | -31.13M | -41.79M | -52.04M | -108.53M | -187.09M | -249.13M | -439.89M | -600.85M |
| Pretax Margin % | - | -2.07% | -1.04% | -2.52% | -6.37% | -7.04% | -37.99% | - |
| Income Tax | 105K | 0 | -4.37M | -371K | 0 | -420K | -3.52M | -753K |
| Effective Tax Rate % | 1% | 1% | 0.92% | 1% | 1% | 1% | 0.99% | 1% |
| Net Income | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M |
| Net Margin % | - | -2.07% | -0.95% | -2.52% | -6.37% | -7.03% | -37.68% | - |
| Net Income Growth % | - | -0.34% | -0.14% | -1.27% | -0.73% | -0.33% | -0.75% | -0.38% |
| Net Income (Continuing) | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.85 | -1.15 | -1.31 | -1.62 | -2.47 | -3.08 | -3.86 | -3.58 |
| EPS Growth % | - | -0.35% | -0.14% | -0.24% | -0.52% | -0.25% | -0.25% | 0.07% |
| EPS (Basic) | -0.85 | -1.15 | -1.31 | -1.62 | -2.47 | -3.08 | -3.86 | -3.58 |
| Diluted Shares Outstanding | 36.47M | 36.47M | 36.47M | 66.6M | 72.81M | 80.63M | 113.15M | 167.74M |
| Basic Shares Outstanding | 36.47M | 36.47M | 36.47M | 66.6M | 72.81M | 80.63M | 113.15M | 167.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.44M | 85.43M | 133.98M | 454.12M | 589.77M | 660.18M | 1.88B | 2.33B |
| Cash & Short-Term Investments | 9.08M | 69.59M | 122.76M | 440.74M | 577.05M | 644.94M | 1.85B | 2.29B |
| Cash Only | 9.08M | 69.59M | 16.66M | 104.27M | 108.5M | 161.41M | 696.15M | 543.06M |
| Short-Term Investments | 0 | 0 | 106.1M | 336.47M | 468.56M | 483.53M | 1.16B | 1.75B |
| Accounts Receivable | 0 | 7.3M | 8.74M | 6.39M | 5.93M | 4.67M | 1.25M | 0 |
| Days Sales Outstanding | - | 132.19 | 63.73 | 54.29 | 73.63 | 48.21 | 39.53 | - |
| Inventory | 0 | 6.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 47.14 | - | - | - | - | - | - |
| Other Current Assets | 0 | 6.6M | 0 | 0 | 0 | 10.57M | 25.07M | 38.33M |
| Total Non-Current Assets | 5.64M | 85.16M | 86.55M | 113.28M | 148.22M | 151.75M | 182.42M | 230.67M |
| Property, Plant & Equipment | 5.25M | 6.87M | 7.15M | 36.34M | 71.24M | 73.74M | 100.01M | 141.82M |
| Fixed Asset Turnover | - | 2.93x | 7.00x | 1.18x | 0.41x | 0.48x | 0.12x | - |
| Goodwill | 0 | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
| Intangible Assets | 0 | 63.08M | 62.01M | 60.95M | 59.88M | 58.81M | 57.74M | 56.67M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 383K | 593K | 2.78M | 1.39M | 2.5M | 4.59M | 10.06M | 17.57M |
| Total Assets | 15.08M | 170.59M | 220.53M | 567.4M | 737.99M | 811.93M | 2.06B | 2.56B |
| Asset Turnover | - | 0.12x | 0.23x | 0.08x | 0.04x | 0.04x | 0.01x | - |
| Asset Growth % | - | 10.31% | 0.29% | 1.57% | 0.3% | 0.1% | 1.54% | 0.24% |
| Total Current Liabilities | 7.6M | 30.55M | 43.05M | 47.18M | 60.35M | 61.98M | 143.85M | 163.91M |
| Accounts Payable | 3.35M | 5.24M | 11.4M | 12.61M | 14.06M | 21.31M | 61.79M | 54.43M |
| Days Payables Outstanding | 46.03 | 37.41 | 45.35 | 34.8 | 27.45 | 30.73 | 54.84 | 33.54 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 2.55M | 6.06M | 5.73M | 7.83M | 10.16M | 13.79M | 27.51M | 31.36M |
| Current Ratio | 1.24x | 2.80x | 3.11x | 9.63x | 9.77x | 10.65x | 13.06x | 14.20x |
| Quick Ratio | 1.24x | 2.58x | 3.11x | 9.63x | 9.77x | 10.65x | 13.06x | 14.20x |
| Cash Conversion Cycle | - | 141.91 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.95M | 43.38M | 24.94M | 45.55M | 75.07M | 64.76M | 91.66M | 129.18M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 28.99M | 60.42M | 57.43M | 80.58M | 122.97M |
| Deferred Tax Liabilities | 0 | 12.19M | 7.82M | 7.44M | 7.44M | 7.03M | 3.12M | 2.35M |
| Other Non-Current Liabilities | 2.95M | 2.77M | 2.4M | 632K | 634K | 301K | 7.97M | 3.86M |
| Total Liabilities | 10.55M | 73.93M | 67.99M | 92.72M | 135.42M | 126.74M | 235.51M | 293.1M |
| Total Debt | 0 | 147K | 0 | 32.66M | 66.63M | 64.2M | 87.94M | 135.84M |
| Net Debt | -9.08M | -69.44M | -16.66M | -71.6M | -41.86M | -97.21M | -608.2M | -407.22M |
| Debt / Equity | - | 0.00x | - | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -302.22x | -347.66x | -510.57x | -1559.11x | -15667.33x | - | - | - |
| Total Equity | 4.53M | 96.66M | 152.53M | 474.68M | 602.57M | 685.19M | 1.83B | 2.27B |
| Equity Growth % | - | 20.33% | 0.58% | 2.11% | 0.27% | 0.14% | 1.67% | 0.24% |
| Book Value per Share | 0.12 | 2.65 | 4.18 | 7.13 | 8.28 | 8.50 | 16.14 | 13.50 |
| Total Shareholders' Equity | 4.53M | 96.66M | 152.53M | 474.68M | 602.57M | 685.19M | 1.83B | 2.27B |
| Common Stock | 0 | 0 | 0 | 7K | 8K | 9K | 16K | 18K |
| Retained Earnings | -67.93M | -109.72M | -157.39M | -265.55M | -452.64M | -701.34M | -1.14B | -1.74B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 74K | 116K | -376K | -1.78M | 544K | 1.32M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -25.15M | 1.21M | -49.62M | -100.06M | -147.18M | -224.4M | -350.57M | -557.44M |
| Operating CF Margin % | - | 0.06% | -0.99% | -2.33% | -5.01% | -6.34% | -30.27% | - |
| Operating CF Growth % | - | 1.05% | -41.9% | -1.02% | -0.47% | -0.52% | -0.56% | -0.59% |
| Net Income | -31.13M | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M |
| Depreciation & Amortization | 1.19M | 1.76M | 3.34M | 6.54M | 7.33M | 9.66M | 9.31M | 11.82M |
| Stock-Based Compensation | 141K | 855K | 0 | 8.89M | 20.72M | 31.2M | 0 | 0 |
| Deferred Taxes | 0 | 201K | -4.37M | -375K | 0 | -419K | -3.91M | -762K |
| Other Non-Cash Items | 549K | 2.12M | 3.53M | 1.34M | 3.13M | -2.64M | 39.73M | 30.43M |
| Working Capital Changes | 4.65M | 38.06M | -4.46M | -8.3M | 8.72M | -13.49M | 40.66M | 1.17M |
| Change in Receivables | 0 | -7.3M | -1.43M | 2.34M | 464K | 1.26M | 3.42M | 1.25M |
| Change in Inventory | 0 | 0 | 0 | -2.34M | 7.68M | 0 | 0 | 0 |
| Change in Payables | 1.97M | 109K | 5.26M | 305K | 2.24M | 7.29M | 32.47M | -6.46M |
| Cash from Investing | -1.57M | -1.34M | -101.97M | -234.23M | -142.12M | -24.12M | -342.6M | -554.39M |
| Capital Expenditures | -1.57M | -1.5M | -2.59M | -2.93M | -6.53M | -10.82M | -7.73M | -10.31M |
| CapEx % of Revenue | - | 0.07% | 0.05% | 0.07% | 0.22% | 0.31% | 0.67% | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -231.3M | -135.59M | -13.3M | 0 | 0 |
| Cash from Financing | 22.66M | 60.85M | 98.66M | 422.78M | 294.18M | 301.43M | 1.23B | 959.41M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 22.66M | 289K | 0 | 2.71M | 2.94M | 3.39M | 836.81M | 284K |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -26.72M | -286K | -52.2M | -103M | -153.71M | -235.22M | -358.3M | -567.74M |
| FCF Margin % | - | -0.01% | -1.04% | -2.4% | -5.23% | -6.65% | -30.94% | - |
| FCF Growth % | - | 0.99% | -181.53% | -0.97% | -0.49% | -0.53% | -0.52% | -0.58% |
| FCF per Share | -0.73 | -0.01 | -1.43 | -1.55 | -2.11 | -2.92 | -3.17 | -3.38 |
| FCF Conversion (FCF/Net Income) | 0.81x | -0.03x | 1.04x | 0.93x | 0.79x | 0.90x | 0.80x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -686.98% | -82.6% | -38.25% | -34.49% | -34.74% | -38.63% | -34.75% | -29.33% |
| Return on Invested Capital (ROIC) | - | -266.82% | -49.77% | -30.81% | -29.26% | -33.73% | -40.46% | -33.62% |
| Gross Margin | - | -153.33% | -83.36% | -207.68% | -536.09% | -615.3% | -3451.33% | - |
| Net Margin | - | -207.24% | -95.25% | -251.63% | -636.58% | -702.95% | -3768.28% | - |
| Debt / Equity | - | 0.00x | - | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x |
| Interest Coverage | -302.22x | -347.66x | -510.57x | -1559.11x | -15667.33x | - | - | - |
| FCF Conversion | 0.81x | -0.03x | 1.04x | 0.93x | 0.79x | 0.90x | 0.80x | 0.93x |
| Revenue Growth | - | - | 148.16% | -14.1% | -31.62% | 20.38% | -67.27% | -100% |
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Collaboration Revenue Member | - | 29.39M | 35.38M |
| Collaboration Revenue Member Growth | - | - | 20.38% |
| Collaboration Revenue Related Party | 42.98M | - | - |
| Collaboration Revenue Related Party Growth | - | - | - |
Revolution Medicines, Inc. (RVMD) saw revenue decline by 100.0% over the past year.
Revolution Medicines, Inc. (RVMD) reported a net loss of $961.0M for fiscal year 2024.
Revolution Medicines, Inc. (RVMD) has a return on equity (ROE) of -29.3%. Negative ROE indicates the company is unprofitable.
Revolution Medicines, Inc. (RVMD) had negative free cash flow of $777.1M in fiscal year 2024, likely due to heavy capital investments.